Attention-deficit-hyperactivity disorder and reward deficiency syndrome

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 5, 2008, Pages 893-917

  Blum, Kenneth ^a,e,f,g,h   Chen, Amanda Lih Chuan ^b   Braverman, Eric R ^c,g   Comings, David E ^d   Chen, Thomas J H ^b   Arcuri, Vanessa ^g   Blum, Seth H ^e   Downs, Bernard W ^e,f   Waite, Roger L ^e   Notaro, Alison ^g   Lubar, Joel ^h   Williams, Lonna ^e   Prihoda, Thomas J ⁱ   Palomo, Tomas ^j   Oscar Berman, Marlene ^k  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e Synapatamine Inc ^*  (United States)

^f Allied Nutraceutical Research   (United States)

^g Path Medical Research Foundation   (United States)

^h UNIVERSITY OF TENNESSEE   (United States)

ⁱ University of Texas Health Science Center at San Antonio   (United States)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^k BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Attention deficit hyperactivity disorder (ADHD); Genes; Neurophysiology deficits; Reward deficiency syndrome; Reward dependence; Treatment

Indexed keywords

AMPHETAMINE; CENTRAL STIMULANT AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE BETA MONOOXYGENASE; DOPAMINE TRANSPORTER; HERBACEOUS AGENT; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO; PROBIOTIC AGENT; SEROTONIN TRANSPORTER; VITAMIN;

ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DNA POLYMORPHISM; ELECTROPHYSIOLOGY; GENE EXPRESSION; GENETIC DISORDER; HETEROZYGOSITY; HUMAN; NEUROPATHOLOGY; NEUROTRANSMITTER RELEASE; REVIEW; REWARD DEFICIENCY SYNDROME; VITAMIN SUPPLEMENTATION;

EID: 56849084636     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Andreazza AC, Frey BN, Valvassori SS, et al. 2007. DNA damage in rats after treatment with methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry, 31:1282-8.
2. APA. 1994. Diagnostic and statistical manual of mental disorders (DSM-IV). Washington, D.C: American Psychiatric Association.
3. APA. 2000. Diagnostic and statistical manual of the American Psychiatric Association. Washington, DC: American Psychiatric Association.
4. Arcos-Burgos M, Castellanos FX, Pineda D, et al. 2004. Attention-deficit/ hyperactivity disorder in a population isolate: linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11. Am J Hum Genet, 75:998-1014.
5. Asherson P, Kuntsi J, Taylor E. 2005. Unravelling the complexity of attention-deficit hyperactivity disorder: a behavioural genomic approach. Br J Psychiatry, 187:103-5.
6. August GJ, Stewart MA. 1983. Familial subtypes of childhood hyperactivity. J Nerv Ment Dis, 171:362-8.
7. Biederman J, Boellner SW, Childress A, et al. 2007a. Lisdexamfetamine Dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry, 62:970-6.
8. Biederman J, Faraone SV, Keenan K, et al. 1992. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and relatives psychiatrically and pediatrically referred samples. Arch Gen Psychiatry, 49:728-38.
9. Biederman J, Gao H, Rogers AK, Spencer TJ. 2006. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children. Biol Psychiatry, 60:1106-10.
10. Biederman J, Spencer TJ, Newcorn JH, et al. 2007b. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology (Berl), 190:31-41.
11. Blum K, Braverman ER, Holder JM, Lubar JF, et al. 2000. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs], 32(Suppl i-iv)1-112.
12. Blum K, Cull JG, Braverman ER, Comings DE. 1996a. Reward deficiency syndrome. Am Sci, 84:132.
13. Blum K, Kozlowski GP. 1990a. Ethanol and neuromodulator influences. A cascade model of reward. In: Ollat H, Parvez S, Parvez H (eds). Alcohol and behaviour: Basic and clinical aspects. Utrecht, Netherlands: VSP.
14. Blum K, Kozlowski GP. 1990b. Ethanol and Neuromodulator influences. A cascade model of reward. In: Ollat H, Parvez S, Parvez H (eds). Alcohol and Behaviour: Basic and Clinical Aspects Progress in Alcohol Research. Utrecht, Netherlands: VSP.
15. Blum K, Meshkin B, Downs BW 2006a. DNA based customized nutraceutical "gene therapy" utilizing a genoscore: a hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human. Med Hypotheses, 66:1008-18.
16. Blum K, Meshkin B, Downs BW. 2006b. DNA based customized nutraceutical "gene therapy" utilizing a genoscore: a hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human. Med Hypotheses, 66:1008-18.
17. Blum K, Noble EP, Sheridan PJ, et al. 1990. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA, 263:2055-60.
18. Blum K, Payne JE. 1991. Alcohol and the addictive brain: new hope for alcoholics from biogenetic research. New York: Free Press. xiv, 320 p.
19. Blum K, Sheridan PJ, Wood RC, et al. 1996b. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med, 89:396-400.
20. Blum K, Trachtenberg MC. 1988. Neurogenetic deficits caused by alcoholism: restoration by SAAVE, a neuronutrient intervention adjunct. J Psychoactive Drugs, 20:297-313.
21. Blum K, Trachtenberg MC, Elliott CE, et al. 1988. Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAA VE. Alcohol, 5:481-93.
22. Bowirrat A, Oscar-Berman M. 2005. Relationship between dopaminergic neurotransmission, alcoholism, and Reward Deficiency Syndrome. Am J Med Genet B Neuropsychiatr Genet, 132:29-37.
23. Braverman ER, Chen TJ, Schoolfield J, et al. 2006. Delayed P300 latency correlates with abnormal Test of Variables of Attention (TOVA) in adults and predicts early cognitive decline in a clinical setting. Adv Ther, 23:582-600.
24. Brookes K, Xu X, Chen W, et al. 2006. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry, 11:934-53.
25. Cantwell DP. 1972. Psychiatric illness in the families of hyperactive children. Arch Gen Psychiatry, 27:414-7.
26. Cantwell DP. 1976. Genetic factors in the hyperkinetic syndrome. J Am Acad Child Psychiatry, 15:214-23.
27. Castellanos FX, Lau E, Tayebi N, et al. 1998. Lack of an association between a dopamine-4 receptor polymorphism and attention-deficit/ hyperactivity disorder: genetic and brain morphometric analyses. Mol Psychiatry, 3:431-4.
28. CHADD. 2007. CHADD's educators manual. Landover, MD: CHADD.
29. Chen TJ, Blum K, Payte JT, et al. 2004. Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. Med Hypotheses, 63:538-48.
30. Cloninger CR, Svrakic DM, Przybeck TR. 1993. A psychobiological model of temperament and character. Arch Gen Psychiatry, 50:975-90.
31. Comings DE. 2001. Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders. Ann N Y Acad Sci, 931:50-83.
32. Comings DE, Chen TJ, Blum K, et al. 2005. Neurogenetic interactions and aberrant behavioral co-morbidity of attention deficit hyperactivity disorder (ADHD): dispelling myths. Theor Biol Med Model, 2:50doi:10.1186/1742-4682-2-50.
33. Comings DE, Comings BG, Muhleman D, et al. 1991. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA, 266:1793-800.
34. Comings DE, Gade-Andavolu R, Gonzalez N, et al. 2000. Multivariate analysis of associations of 42 genes in ADHD, ODD and conduct disorder. Clin Genet, 58:31-40.
35. Comings DE, Wu S, Chiu C, et al. 1996. Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes - DRD2, D beta H, and DAT1. Am J Med Genet, 67:264-88.
36. Conners CK. 2006. CRS-R (Conners'Rating Scales-Revised). Minneapolis, MN: Pearson Assessment Group.
37. Cook EH, Jr., Stein MA, Krasowski MD, et al. 1995. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet, 56:993-8.
38. Defrance JF, Hymel C, Trachtenberg MC, et al. 1977. Enhancement of attentional processing by Kantroll in healthy humans: A pilot study. Clin Electroencephalography, 28:68-75.
39. Dyr W, McBride WJ, Lumeng L, et al. 1993. Effects of D1 and D2 dopamine receptor agents on ethanol consumption in the high-alcohol-drinking (HAD) line of rats. Alcohol, 10:207-12.
40. Faraone SV. 2003. Report from the 4th international meeting of the attention deficit hyperactivity disorder molecular genetics network. Am J Med Genet B Neuropsychiatr Genet, 121:55-9.
41. Faraone SV, Biederman J, Keenan K, et al. 1991. A family-genetic study of girls with DSM-III attention deficit disorder. Am J Psychiatry, 148:112-7.
42. Farde L, Gustavsson JP, Jonsson E. 1997. D2 dopamine receptors and personality traits. Nature, 385(6617):590.
43. Gadow KD, Nolan EE, Sverd J. 1992. Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short-term behavioral effects in school settings. J Am Acad Child Adolesc Psychiatry, 31:462-71.
44. Gill M, Daly G, Heron S, et al. 1997. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry, 2:311-3.
45. Heiser P, Friedel S, Dempfle A, et al. 2004. Molecular genetic aspects of attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev, 28:625-41.
46. Hiebel AC, Lee YS, Bilsky E, et al. 2007. Probes for narcotic receptor mediated phenomena. 34. synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. J Med Chem, 50:65-75.
47. Howell DC, Huessy HR, Hassuk B. 1985. Fifteen-year follow-up of a behavioral history of attention deficit disorder. Pediatrics, 76:185-90.
48. Imperato A, Di Chiara G. 1988. Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis. Eur J Pharmacol, 156:385-93.
49. Inkster B, Muglia P, Jain U, et al. 2004. Linkage disequilibrium analysis of the dopamine beta-hydroxylase gene in persistent attention deficit hyperactivity disorder. Psychiatr Genet, 14:117-20.
50. Jönsson E, Sedvall G, Brene S, et al. 1996. Dopamine-related genes and their relationships to monoamine metabolites in CSF. Biol Psychiatry, 40:1032-43.
51. Kent L, Green E, Hawi Z, et al. 2005. Association of the paternally transmitted copy of common Valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene with susceptibility to ADHD. Mol Psychiatry, 10:939-43.
52. Kimberg DY, D'Esposito M, Farah MJ. 1997. Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport, 8:3581-5.
53. Kirley A, Lowe N, Hawi Z, et al. 2003. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B Neuropsychiatr Genet, 121:50-4.
54. Koob GF, Bloom FE. 1988. Cellular and molecular mechanisms of drug dependence. Science, 242(4879):715-723.
55. Krause J, Dresel SH, Krause KH, et al. 2003. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev, 27:605-13.
56. Krause J, Krause KH, Dresel SH, et al. 2006. ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine. Dialogues Clin Neurosci, 8:29-36.
57. Krause J, la Fougere C, Krause KH, et al. 2005. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Europ Arch Psychiatry Clin Neurosci, 255:428-31.
58. la Fougere C, Krause J, Krause KH, et al. 2006. Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder Nuclear Med Commun, 27:733-7.
59. LaHoste GJ, Swanson JM, Wigal SB, et al. 1996. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry, 1:121-4.
60. Larsson H, Lichtenstein P, Larsson JO. 2006. Genetic contributions to the development of ADHD subtypes from childhood to adolescence. J Am Acad Child Adolesc Psychiatry, 45:973-81.
61. Laurin N, Misener VL, Crosbie J, et al. 2005. Association of the calcyon gene (DRD1IP) with attention deficit/hyperactivity disorder. Mol Psychiatry, 10:1117-25.
62. Le Moal M, Simon H. 1991. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev, 71:155-234.
63. Lee HJ, Lee HS, Kim YK, et al. 2003. D2 and D4 dopamine receptor gene polymorphisms and personality traits in a young Korean population. Am J Med Genet B Neuropsychiatr Genet, 121:44-9.
64. Li D, Sham PC, Owen MJ, He L. 2006. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet, 15:2276-84.
65. Lou HC, Andresen J, Steinberg B, et al. 1999. The striatum in a putative cerebral network activated by verbal awareness in normals and in ADHD children. Eur J Neurol, 5:67-74.
66. Lubar JF. 1991. Discourse on the development of EEG diagnostics and biofeedback for attention-deficit/hyperactivity disorders. Biofeedback Self Regul, 16:201-25.
67. Madras BK, Miller GM, Fischman AJ. 2005. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry, 57:1397-409.
68. Malison RT, McDougle CJ, van Dyck CH, et al. 1995. [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry, 152:1359-61.
69. McBride WJ, Chernet E, Dyr W, et al. 1993. Densities of dopamine D2 receptors are reduced in CNS regions of alcohol-preferring P rats. Alcohol, 10:387-90.
70. McBride WJ, Guan XM, Chernet E, Lumeng L, Li TK. 1994. Regional serotonin1A receptors in the CNS of alcohol-preferring and -nonpreferring rats. Pharmacol Biochem Behav, 49:7-12.
71. Mill J, Caspi A, Williams BS, et al. 2006. Prediction of heterogeneity in intelligence and adult prognosis by genetic polymorphisms in the dopamine system among children with attention-deficit/hyperactivity disorderi evidence from 2 birth cohorts. Arch Gen Psychiatry, 63:462-9.
72. Miller D, Blum K. 2008. Overload: Attention deficit disorder and the addictive brain. Salt Lake City, Utah: Woodland Publishing Company.
73. Noble EP. 2003. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet, 116:103-25.
74. Noble EP, Berman SM, Ozkaragoz TZ, Ritchie T. 1994. Prolonged P300 latency in children with the D2 dopamine receptor A1 allele. Am J Hum Genet, 54:658-68.
75. Noble EP, Gottschalk LA, Fallon JH, et al. 1997. D2 dopamine receptor polymorphism and brain regional glucose metabolism. Am J Med Genet, 74:162-6.
76. Olds J. 1956. A preliminary mapping of electrical reinforcing effects in the rat brain. J Comp Physiol Psychol, 49:281-5.
77. Ollat H, Parvez S, Parvez H. 1990. Alcohol and behaviour: basic and clinical aspects. Progress in alcohol research. Utrecht, Netherlands: VSP. p vi, 285 p.
78. Ortiz J, Fitzgerald LW, Charlton M, et al. 1995. Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system. Synapse, 21:289-98.
79. Pauls DL, Leckman JF. 1986. The inheritance of Gilles de la Tourette's syndrome and associated behaviors. Evidence for autosomal dominant transmission. N Engl J Med, 315:993-7.
80. Perwien AR, Kratochvil CJ, Faries DE, et al. 2006. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes? J Child Adolesc Psychopharmacol, 16:713-24.
81. Pohjalainen T, Rinne JO, Nagren K, et al. 1998. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry, 3:256-60.
82. Rothman RB, Blough BE, Baumann MH. 2007. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J, 9:E1-10.
83. Russell VA, Lamm MC, Taljaard JJ. 1988. Effect of ethanol on [3H]dopamine release in rat nucleus accumbens and striatal slices. Neurochem Res, 13:487-92.
84. Safer DJ. 1973. "A familial factor in minimal brain dysfunction. Behav Genet, 3:175-86.
85. Seeman P, Madras BK. 1998. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry, 3:386-96.
86. Shaw P, Gornick M, Lerch J, et al. 2007. Polymorphisms of the dopamine d4 receptor, clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry, 64:921-31.
87. Shaywitz BA, Yager RD, Klopper JH. 1976. Selective brain dopamine depletion in developing rats: an experimental model of minimal brain dysfunction. Science, 191(4224):305-8.
88. Smith KM, Bauer L, Fischer M, et al. 2005. Identification and characterization of human NR4A2 polymorphisms in attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet, 133:57-63.
89. Spencer T, Biederman J, Heiligenstein J, et al. 2001. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol, 11:251-65.
90. Spencer TJ, Faraone SV, Michelson D, et al. 2006. Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry, 67:415-20.
91. Stein L, Belluzzi J. 1986. Second messengers, natural rewards, and drugs of abuse. Clin Neuropharmacol, 9(Suppl 4):205-7.
92. Swanson JM, Kinsbourne M, Nigg J, et al. 2007. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev, 17:39-59.
93. Thanos PK, Michaelides M, Benveniste H, et al. 2007. Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents. Pharmacol Biochem Behav, 87:426-33.
94. TOVA. 2006. T.O.V.A. (Test of Variables of Attention). Los Alamitos, CA: The TOVA Company.
95. Turic D, Langley K, Williams H, et al. 2005a. A family based study implicates solute carrier family 1-member 3 (SLC1A3) gene in attention-deficit/hyperactivity disorder. Biol Psychiatry, 57:1461-6.
96. Turic D, Williams H, Langley K, et al. 2005b. A family based study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD). Am J Med Genet B Neuropsychiatr Genet, 133:64-7.
97. Volkow ND, Ding YS, Fowler JS, et al. 1995. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry, 52:456-63.
98. Volkow ND, Wang GJ, Newcorn J, et al. 2007. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry, 64:932-40.
99. Waldman ID, Mohr JH, Abramowitz A, et al. 1998. The relation between childhood antisocial behavior and the dopamine transporter gene (DAT1). Mediation via hyperactivity-impulsivity. Am J Med Gen B Neuropsychiatr Genet, 81:451-556.
100. Wallis D, Russell HF, Muenke M. 2008. Genetics of attention deficit/ hyper-activity disorder. J Pediatr Psychol, Jun 3 [Epub ahead of print].
101. Welner Z, Welner A, Stewart M, et al. 1977. A controlled study of siblings of hyperactive children. J Nerv Ment Dis, 165:110-7.
102. Wilens TE, Gignac M, Swezey A, et al. 2006. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry, 45:408-14.
103. Willerman L. 1973. Activity level and hyperactivity in twins. Child Dev, 44:288-93.
104. Winsberg BG, Comings DE. 1999. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry, 38:1474-7.
105. Wise RA, Bozarth MA. 1984. Brain reward circuitry: four circuit elements "wired" in apparent series. Brain Res Bull, 12:203-8.
106. Wolf SS, Jones DW, Knable MB, et al. 1996. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science, 273(5279):1225-7.
107. Wolraich ML, Hannah YN, Baumgaertel A, Feurer ID. 1998. Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a county-wide sample. J Dev Behav Pediatr, 19:162-8.
108. Zametkin AJ, Nordahl TE, Gross M, et al. 1990. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med, 323:1361-6.
109. Zhou FC, Bledsoe S, Lumeng L, Li TK. 1991. Immunostained serotonergic fibers are decreased in selected brain regions of alcohol-preferring rats. Alcohol, 8:425-31.